<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40"><head><meta http-equiv=Content-Type content="text/html; charset=utf-8"><meta name=Generator content="Microsoft Word 12 (filtered medium)"><!--[if !mso]><style>v\:* {behavior:url(#default#VML);}
o\:* {behavior:url(#default#VML);}
w\:* {behavior:url(#default#VML);}
.shape {behavior:url(#default#VML);}
</style><![endif]--><title>THE "NEW" PROSTATE CANCER INFOLINK</title><style><!--
/* Font Definitions */
@font-face
{font-family:Helvetica;
panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:Georgia;
panose-1:2 4 5 2 5 4 5 2 3 3;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0cm;
margin-bottom:.0001pt;
font-size:12.0pt;
font-family:"Times New Roman","serif";}
h1
{mso-style-priority:9;
mso-style-link:"Heading 1 Char";
mso-margin-top-alt:auto;
margin-right:0cm;
mso-margin-bottom-alt:auto;
margin-left:0cm;
font-size:24.0pt;
font-family:"Times New Roman","serif";
font-weight:bold;}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:blue;
text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-priority:99;
color:purple;
text-decoration:underline;}
p
{mso-style-priority:99;
mso-margin-top-alt:auto;
margin-right:0cm;
mso-margin-bottom-alt:auto;
margin-left:0cm;
font-size:12.0pt;
font-family:"Times New Roman","serif";}
span.Heading1Char
{mso-style-name:"Heading 1 Char";
mso-style-priority:9;
mso-style-link:"Heading 1";
font-family:"Cambria","serif";
color:#365F91;
font-weight:bold;}
span.EmailStyle19
{mso-style-type:personal-reply;
font-family:"Calibri","sans-serif";
color:#1F497D;}
.MsoChpDefault
{mso-style-type:export-only;
font-size:10.0pt;}
@page WordSection1
{size:612.0pt 792.0pt;
margin:72.0pt 72.0pt 72.0pt 72.0pt;}
div.WordSection1
{page:WordSection1;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]--></head><body lang=EN-CA link=blue vlink=purple><div class=WordSection1><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'>If J & J, parent of Janssen, loses the appeal of this cash cow ($5K/patient/month), will it impact Janssen support of PCCN chapters?<o:p></o:p></span></p><p class=MsoNormal><o:p> </o:p></p><div style='margin-left:24.0pt;margin-right:24.0pt' id=emailbody><table class=MsoNormalTable border=0 cellpadding=0 width="100%" style='width:100.0%'><tr><td width="99%" valign=top style='width:99.0%;padding:0cm 0cm 0cm 0cm'><h1 style='margin:0cm;margin-bottom:.0001pt'><a href="https://prostatecancerinfolink.net" title="(https://prostatecancerinfolink.net)"><span style='font-size:16.5pt;font-family:"Arial","sans-serif";color:#888888;font-weight:normal;text-decoration:none'>The Prostate Cancer InfoLink</span></a> <o:p></o:p></h1></td><td width="1%" style='width:1.0%;padding:0cm 0cm 0cm 0cm'></td></tr></table><div class=MsoNormal align=center style='text-align:center;line-height:140%'><span style='font-size:10.0pt;line-height:140%;font-family:"Georgia","serif";color:black'><hr size=2 width="100%" align=center></span></div><table class=MsoNormalTable border=0 cellpadding=0 id=itemcontentlist><tr><td style='padding:.75pt .75pt .75pt .75pt'><p style='mso-margin-top-alt:12.0pt;margin-right:0cm;margin-bottom:2.25pt;margin-left:0cm;line-height:16.8pt'><a name=1></a><a href="http://feedproxy.google.com/~r/TheProstateCancerInfolink/~3/UjjTiq7_pd0/?utm_source=feedburner&utm_medium=email"><b><span style='font-size:13.5pt;font-family:"Arial","sans-serif";color:#000099;text-decoration:none'>Might we see generic abiraterone acetate this year?</span></b></a> <o:p></o:p></p><p style='mso-margin-top-alt:6.75pt;margin-right:0cm;margin-bottom:2.25pt;margin-left:0cm;line-height:140%'><span style='font-size:10.0pt;line-height:140%;font-family:"Georgia","serif";color:#555555'>Posted: 18 Jan 2018 10:52 AM PST<o:p></o:p></span></p><div><p class=MsoNormal style='line-height:140%'><span style='font-size:10.0pt;line-height:140%;font-family:"Georgia","serif";color:black'>On Wednesday the U.S. Patent Trial and Appeal Board invalidated the last remaining patent on abiraterone acetate (Zytiga), making it possible that generic forms of abiraterone acetate would be available in 2018 (at least in the US). We can expect Johnson & Johnson to appeal this decision, so the early availability of generic abiraterone acetate […]<o:p></o:p></span></p></div></td></tr></table><p class=MsoNormal style='line-height:140%'><span style='font-size:10.0pt;line-height:140%;font-family:"Georgia","serif";color:black;display:none'><o:p> </o:p></span></p><table class=MsoNormalTable border=1 cellpadding=0 width="100%" style='width:100.0%;border:none;border-top:solid #999999 1.0pt' id=footer><tr><td style='border:none;padding:3.0pt .75pt .75pt .75pt'><p class=MsoNormal style='mso-margin-top-alt:0cm;margin-right:4.5pt;margin-bottom:14.4pt;margin-left:0cm'><span style='font-size:8.5pt;font-family:"Helvetica","sans-serif";color:#333333'>You are subscribed to email updates from <a href="https://prostatecancerinfolink.net">THE "NEW" PROSTATE CANCER INFOLINK</a>.<br><br><o:p></o:p></span></p></td><td valign=top style='border:none;padding:3.0pt .75pt .75pt .75pt'><p class=MsoNormal align=right style='mso-margin-top-alt:0cm;margin-right:4.5pt;margin-bottom:14.4pt;margin-left:0cm;text-align:right'><span style='font-size:8.5pt;font-family:"Helvetica","sans-serif";color:#333333'>Email delivery powered by Google<o:p></o:p></span></p></td></tr><tr><td colspan=2 style='border:none;padding:3.0pt .75pt .75pt .75pt'></td></tr></table><p class=MsoNormal><o:p> </o:p></p></div></div></body></html>